Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for pulmonary hypertension due to fibrosing mediastinitis
ChiCTR2000034808Phase 4Recruiting
- Sponsor
- Gansu Provincial People's Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in pulmonary arterial hypertension (PAH) and fibrosing mediastinitis (FM) comparing Experimental group (ambrisentan) with Control group (placebo) (2 arms). Primary endpoints: 6-minute walk distance and WHO functional classification. Started Jul 2020; status: recruiting.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)fibrosing mediastinitis (FM)
Beyond the preview
Go deeper on ChiCTR2000034808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034808.